Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts
Journal of Clinical Medicine · 07.05.2025 · 14 (9) · 3250
DOI: 10.3390/jcm14093250 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 07.05.2025. Verfasst von Paschalis Karakasis und 6 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, Hippokration General Hospital, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 223 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atrial fibrillation (AF) is increasingly recognized not merely as an arrhythmia, but as a clinical manifestation of atrial cardiomyopathy (AtCM)—a progressive, multifaceted disease of the atrial myocardium involving structural, electrical, mechanical, and molecular remodeling. AtCM often precedes AF onset, sustains its perpetuation, and contributes to thromboembolic risk independently of rhythm status. Emerging evidence implicates diverse pathophysiological drivers of AtCM, including inflammation, epicardial adipose tissue, metabolic dysfunction, oxidative stress, ageing, and sex-specific remodeling. The NLRP3 inflammasome has emerged as a central effector in atrial inflammation and remodeling. Gut microbial dysbiosis, lipid dicarbonyl stress, and fibro-fatty infiltration are also increasingly recognized as contributors to arrhythmogenesis. AtCM is further linked to atrial functional valve regurgitation and adverse outcomes in AF. Therapeutically, substrate-directed strategies—ranging from metabolic modulation and immunomodulation to early rhythm control—offer promise for altering the disease trajectory. This review synthesizes mechanistic insights into AtCM and discusses emerging therapeutic paradigms that aim not merely to suppress arrhythmia but to modify the underlying substrate. Recognizing AF as a syndrome of atrial disease reframes management strategies and highlights the urgent need for precision medicine approaches targeting the atrial substrate.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Second Department of Cardiology, Hippokration General Hospital, Medical School, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
- First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece.
- Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
ORCID-Profile: Paschalis Karakasis, Panagiotis Theofilis, Panayotis K Vlachakis, Nikolaos Ktenopoulos, Dimitrios Patoulias, Antonios P Antoniadis, Nikolaos Fragakis
Zitieren
APA
Karakasis, P., Theofilis, P., Vlachakis, P. K., Ktenopoulos, N., Patoulias, D., Antoniadis, A. P., & Fragakis, N. (2025). Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts. Journal of Clinical Medicine, 14(9), 3250. https://doi.org/10.3390/jcm14093250
Vancouver
Karakasis P, Theofilis P, Vlachakis PK, Ktenopoulos N, Patoulias D, Antoniadis AP, et al. Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts. Journal of Clinical Medicine. 2025;14(9):3250. doi:10.3390/jcm14093250
BibTeX
@article{Karakasis2025,
author = {Karakasis, Paschalis and Theofilis, Panagiotis and Vlachakis, Panayotis K and Ktenopoulos, Nikolaos and Patoulias, Dimitrios and Antoniadis, Antonios P and Fragakis, Nikolaos},
title = {Atrial Cardiomyopathy in Atrial Fibrillation: Mechanistic Pathways and Emerging Treatment Concepts},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {9},
pages = {3250},
doi = {10.3390/jcm14093250}
}
EUVIMED